1.	Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Phase: Phase IV Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 13 to 15 at first immunization Sponsor: Other Protocol IDs: HPV CSP01, NCT00956553
2.	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Phase: Phase IV Type: Prevention Status: Approved-not yet active Age: 13 to 15 Sponsor: Other Protocol IDs: 37207, NCT01021904
3.	Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Phase: Phase IV Type: Prevention Status: Active Age: 15 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 109823, NCT01031069
4.	Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase: Phase IV Type: Prevention Status: Active Age: 11 to 17 Sponsor: Other Protocol IDs: GardasilMerckGomez-Lobo, NCT01101750
5.	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Phase: Phase IV Type: Prevention Status: Approved-not yet active Age: 18 to 26 Sponsor: Other Protocol IDs: CIHR-MOP-125949, IIS #38265, NCT01824537
6.	Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study Phase: Phase III Type: Prevention Status: Active Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113621, NCT01190189
7.	The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study Phase: Phase III Type: Prevention Status: Active Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113618, NCT01249365
8.	Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study Phase: Phase III Type: Prevention Status: Active Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 114379, NCT01418937
9.	Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine in Healthy Female Children Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 4 to 6 and 15 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 115887, 2011-005604-15, NCT01627561
10.	Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5) Phase: Phase III Type: Prevention Status: Active Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: V503-003, 2012-001375-36, NCT01651949
11.	Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine Phase: Phase III Type: Prevention Status: Active Age: 18 to 45 Sponsor: Other Protocol IDs: HPV-PRO-003, NCT01735006
12.	Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 25 Sponsor: Other Protocol IDs: HPV-PRO-002, NCT01356823
13.	A Phase I Clinical Trial of an HPV Therapeutic Vaccine Phase: Phase I Type: Prevention Status: Active Age: 18 to 50 Sponsor: NCI, Other Protocol IDs: 130662, R01CA143130, NCT01653249
14.	Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention Phase: No phase specified Type: Health services research, Prevention Status: Active Age: 9 to 13 Sponsor: Other Protocol IDs: 36448, NCT01096134
15.	A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study Phase: No phase specified Type: Health services research, Prevention, Screening Status: Active Age: 18 to 26 Sponsor: Other Protocol IDs: 33249, NCT01133509
16.	An Intervention Study To Improve HPV Immunization in Haitian and African American Girls Phase: No phase specified Type: Behavioral study, Educational/Counseling/Training, Prevention Status: Active Age: 11 to 15 Sponsor: Other Protocol IDs: H26306, NCT01254669
17.	The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 26 Sponsor: Other Protocol IDs: 2011/02_Medicine, NCT01298869
18.	Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka Phase: No phase specified Type: Prevention Status: Approved-not yet active Age: 10 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113763, NCT01551537